MARTINSRIED (dpa-AFX) - MorphoSys AG (MPSYY.PK) said that DiaSorin S.p.A., a global provider of specialty assays, has taken a license for two recombinant HuCAL antibodies. The antibodies, which were made by AbD Serotec, MorphoSys's unit for research and diagnostic antibodies, act as recombinant controls for two marketed infectious disease assays. AbD Serotec would receive license fees and royalties on sales of kits comprising the antibodies.
The collaboration between DiaSorin and AbD Serotec brings together DiaSorin's broad expertise in the development, manufacturing and marketing of immunodiagnostic test systems and AbD Serotec's recombinant HuCAL antibody generation technology. AbD Serotec has generated two recombinant antibodies in the IgM format, which DiaSorin is implementing into its new diagnostic tests for Measles IgM and Mumps IgM.
According to MorphoSys, the launch of the DiaSorin LIAISON Measles IgM and LIAISON Mumps IgM assays provides the first and only fully automated immunoassays on the diagnostic market for the serological determination of the immunity status of patients to measles and mumps viruses.
Copyright RTT News/dpa-AFX
© 2012 AFX News
